News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,151 Results
Type
Article (39459)
Company Profile (254)
Press Release (653438)
Section
Business (204224)
Career Advice (2009)
Deals (35430)
Drug Delivery (93)
Drug Development (81029)
Employer Resources (169)
FDA (16142)
Job Trends (14844)
News (345192)
Policy (32495)
Tag
Academia (2536)
Alliances (49384)
Alzheimer's disease (1314)
Approvals (16123)
Artificial intelligence (200)
Bankruptcy (357)
Best Places to Work (11646)
Biotechnology (182)
Breast cancer (225)
Cancer (1714)
Cardiovascular disease (128)
Career advice (1671)
CAR-T (122)
Cell therapy (354)
Clinical research (65309)
Collaboration (663)
Compensation (370)
COVID-19 (2569)
C-suite (160)
Data (1630)
Diabetes (211)
Diagnostics (6285)
Earnings (85460)
Employer resources (146)
Events (111005)
Executive appointments (564)
FDA (17042)
Funding (603)
Gene therapy (248)
GLP-1 (648)
Government (4357)
Healthcare (18783)
Infectious disease (2680)
Inflammatory bowel disease (121)
Interviews (311)
IPO (16471)
Job creations (3636)
Job search strategy (1422)
Layoffs (437)
Legal (7887)
Lung cancer (255)
Manufacturing (235)
Medical device (13263)
Medtech (13268)
Mergers & acquisitions (19334)
Metabolic disorders (548)
Neuroscience (1716)
NextGen: Class of 2025 (6520)
Non-profit (4476)
Northern California (2093)
Obesity (306)
Opinion (193)
Patents (162)
People (56902)
Phase I (20348)
Phase II (28776)
Phase III (21411)
Pipeline (711)
Postmarket research (2563)
Preclinical (8588)
Radiopharmaceuticals (241)
Rare diseases (323)
Real estate (5910)
Regulatory (21941)
Research institute (2312)
Resumes & cover letters (350)
Southern California (1792)
Startups (3574)
United States (18468)
Vaccines (611)
Weight loss (208)
Date
Today (92)
Last 7 days (595)
Last 30 days (2621)
Last 365 days (34489)
2025 (4440)
2024 (35251)
2023 (40104)
2022 (51230)
2021 (55762)
2020 (54123)
2019 (46565)
2018 (35041)
2017 (32144)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (716)
Arizona (211)
Asia (37583)
Australia (6155)
California (4769)
Canada (1715)
China (393)
Colorado (218)
Connecticut (230)
Europe (80522)
Florida (688)
Georgia (165)
Illinois (455)
Indiana (259)
Maryland (743)
Massachusetts (3603)
Michigan (198)
Minnesota (336)
New Jersey (1347)
New York (1359)
North Carolina (836)
Northern California (2093)
Ohio (173)
Pennsylvania (1108)
South America (1093)
Southern California (1792)
Texas (703)
Utah (143)
Washington State (468)
693,151 Results for "atara biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Atara to Cut Half Its Workforce Following FDA-Related Setbacks
Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected Ebvallo, a T cell therapy approved in Europe for a transplant-related blood cancer, and placed a clinical hold on the company’s active drug applications.
January 28, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 7, 2025
February 9, 2025
·
1 min read
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market just yet, forcing the company to “significantly reduce expenses.”
January 16, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
January 16, 2025
·
9 min read
Press Releases
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
January 21, 2025
·
5 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.
June 7, 2024
·
2 min read
Deals
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
Atara Biotherapeutics, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 (the “Reverse Stock Split”).
June 17, 2024
·
5 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
Atara Biotherapeutics, Inc. reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
April 5, 2024
·
2 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.
May 3, 2024
·
2 min read
1 of 69,316
Next
